QQ客服 官方微博 反馈留言

	Synthesis and identification of GZD856 as an orally bioavailable Bcr-Abl inhibitor overcoming acquired imatinib resistance.
	Lu, Xiaoyun[7,8]; Zhang, Zhang[7,8]; Ren, Xiaomei[8]; Wang, Deping[8]; Ding, Ke[7,8]
	2017
卷号	32期号:1
URL标识	查看原文
内容类型	期刊论文
URI标识	http://www.corc.org.cn/handle/1471x/4486985
专题	暨南大学
作者单位	1.[7]a School of Pharmacy , Jinan University , Guangzhou , China. 2.[8]b State Key Laboratory of Respiratory Diseases , Guangzhou Institutes of Biomedicine and Health, Chinese Academy of Sciences , Guangzhou , China.
推荐引用方式 GB/T 7714	Lu, Xiaoyun[7,8],Zhang, Zhang[7,8],Ren, Xiaomei[8],et al. Synthesis and identification of GZD856 as an orally bioavailable Bcr-Abl inhibitor overcoming acquired imatinib resistance.[J],2017,32(1).
APA	Lu, Xiaoyun[7,8],Zhang, Zhang[7,8],Ren, Xiaomei[8],Wang, Deping[8],&Ding, Ke[7,8].(2017).Synthesis and identification of GZD856 as an orally bioavailable Bcr-Abl inhibitor overcoming acquired imatinib resistance..,32(1).
MLA	Lu, Xiaoyun[7,8],et al."Synthesis and identification of GZD856 as an orally bioavailable Bcr-Abl inhibitor overcoming acquired imatinib resistance.".32.1(2017).

个性服务

查看访问统计

相关权益政策

暂无数据

收藏/分享

除非特别说明，本系统中所有内容都受版权保护，并保留所有权利。